摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-methyl-2,1-benzisothiazole | 74959-99-2

中文名称
——
中文别名
——
英文名称
6-methyl-2,1-benzisothiazole
英文别名
6-Methyl-2,1-benzothiazole
6-methyl-2,1-benzisothiazole化学式
CAS
74959-99-2
化学式
C8H7NS
mdl
——
分子量
149.216
InChiKey
IOQUWVDJSLIGIS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    41.1
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PIPÉRIDINE 1,4-SUBSTITUÉS
    申请人:CEPHALON INC
    公开号:WO2016205633A1
    公开(公告)日:2016-12-22
    Described herein are 1,4-substituted piperidine compounds according to Formula (I) that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.
    本文描述了按照式(I)的1,4-取代哌啶化合物,这些化合物已经表现出作为脂肪酸合成酶抑制剂的活性。本文还描述了含有所述1,4-取代哌啶化合物的药物组合物,以及通过给予所述化合物或药物配方中的一个或多个来治疗由脂肪酸合成酶介导的疾病的方法。本文还描述了合成所述化合物的方法,包括所述的1,4-取代哌啶化合物和在这些合成中有用的合成中间体。
  • [EN] SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 4-BENZYL ET 4-BENZOYL-PIPÉRIDINE SUBSTITUÉS
    申请人:CEPHALON INC
    公开号:WO2016205590A1
    公开(公告)日:2016-12-22
    Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds. Also described herein are methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.
    本文描述了根据公式I的1,4-取代哌啶化合物,这些化合物已经表现出作为脂肪酸合酶抑制剂的活性。本文还描述了含有所述1,4-取代哌啶化合物的药物组合物。本文还描述了通过给予本文描述的一个或多个化合物或药物配方治疗由脂肪酸合酶介导的疾病的方法。本文还描述了合成所述1,4-取代哌啶化合物以及在这些合成中有用的合成中间体的方法。
  • [EN] HER2 MUTATION INHIBITORS<br/>[FR] INHIBITEURS DE MUTATION HER2
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2022003575A1
    公开(公告)日:2022-01-06
    This invention relates to compounds of Formula (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
    本发明涉及式(I)的化合物及其对映体,以及式(I)及其对映体的药用可接受盐,其中L1、L2、R1、R2、R3和n如本文所定义。本发明还涉及包括这些化合物和盐的药物组合物,以及利用这些化合物、盐和组合物治疗需要的受试者中的异常细胞生长,包括癌症的方法和用途。
  • 1,4-substituted piperidine derivatives
    申请人:89BIO LTD
    公开号:US10221135B2
    公开(公告)日:2019-03-05
    Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.
    本文描述了根据式 I 的 1,4-取代的哌啶化合物,这些化合物已被证明具有脂肪酸合酶抑制剂的活性。本文还描述了含有所述 1,4-取代哌啶化合物的药物组合物,以及通过施用一种或多种本文所述化合物或药物制剂治疗由脂肪酸合成酶介导的疾病的方法。本文还描述了合成所述化合物的方法,包括所述 1,4-取代的哌啶化合物和用于这些合成的合成中间体。
  • Substituted 4-benzyl and 4-benzoyl piperidine derivatives
    申请人:89BIO LTD
    公开号:US10919875B2
    公开(公告)日:2021-02-16
    Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds. Also described herein are methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.
    本文所述的 1,4-取代的哌啶化合物符合式 I,具有脂肪酸合成酶抑制剂的活性。本文还描述了含有所述 1,4-取代哌啶化合物的药物组合物。本文还描述了通过施用一种或多种本文所述化合物或药物制剂来治疗由脂肪酸合成酶介导的疾病的方法。本文还描述了合成所述 1,4-取代的哌啶化合物和用于这些合成的合成中间体的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-(+)-5,5'',6,6'',7,7'',8,8''-八氢-3,3''-二叔丁基-1,1''-二-2-萘酚,双钾盐 (S)-盐酸沙丁胺醇 (S)-溴烯醇内酯 (S)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2-N-Fmoc-氨基甲基吡咯烷盐酸盐 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-3,3''-双([[1,1''-联苯]-4-基)-[1,1''-联萘]-2,2''-二醇 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-2,2'',3,3''-四氢-6,6''-二-9-菲基-1,1''-螺双[1H-茚]-7,7''-二醇 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (6,6)-苯基-C61己酸甲酯 (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,5R)-3,3a,8,8a-四氢茚并[1,2-d]-1,2,3-氧杂噻唑-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aS,8aR)-2-(吡啶-2-基)-8,8a-二氢-3aH-茚并[1,2-d]恶唑 (3aS,3''aS,8aR,8''aR)-2,2''-环戊二烯双[3a,8a-二氢-8H-茚并[1,2-d]恶唑] (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (3S,3aR)-2-(3-氯-4-氰基苯基)-3-环戊基-3,3a,4,5-四氢-2H-苯并[g]吲唑-7-羧酸 (3R,3’’R,4S,4’’S,11bS,11’’bS)-(+)-4,4’’-二叔丁基-4,4’’,5,5’’-四氢-3,3’’-联-3H-二萘酚[2,1-c:1’’,2’’-e]膦(S)-BINAPINE (3-三苯基甲氨基甲基)吡啶 (3-[(E)-1-氰基-2-乙氧基-2-hydroxyethenyl]-1-氧代-1H-茚-2-甲酰胺) (2′′-甲基氨基-1,1′′-联苯-2-基)甲烷磺酰基铝(II)二聚体 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,4S)-Fmoc-4-三氟甲基吡咯烷-2-羧酸 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环